TORCH tests and what they mean.

J L Sever

doi:10.1016/0002-9378(85)90614-3

Home/Archive/PubMed

PubMed · 2990211

TORCH tests and what they mean.

J L Sever

View original source ↗Export metadata ↓

Abstract

TORCH tests can be used to document immunity or recent infections. Many laboratories now offer TORCH tests and there are a large variety of methods, kits, and reporting systems. Some of the TORCH tests are not accurate and should be avoided. In general, we prefer enzyme immunoassays for documentation of past infections or immunity. To demonstrate recent infections with toxoplasmosis and rubella we use IgM enzyme-linked immunosorbent assay tests but for cytomegalovirus and herpes infections we prefer virus isolation. Physicians should send specimens only to laboratories that participate in proficiency surveys or similar tests that document the accuracy of the laboratory. All TORCH test sera should be held by the laboratory for 1 year to permit repeat testing and analysis with subsequent specimens if necessary.

Explore related subjects

Complement Fixation Tests Cytomegalovirus Infections Enzyme-Linked Immunosorbent Assay Female Fluorescent Antibody Technique Hemagglutination Inhibition Tests Hemagglutination Tests Herpesviridae Infections Humans Latex Fixation Tests Pregnancy Reagent Kits, Diagnostic Rubella Serologic Tests Toxoplasmosis Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

J L Sever. 1985-07-01. TORCH tests and what they mean.. https://doi.org/10.1016/0002-9378(85)90614-3

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Using facsimile cascade to assist case searching during a Q fever outbreak.

In September 2002, facsimiles were sent to 360 primary-care physicians alerting them to a local outbreak of Q fever. The physicians subsequently submitted serology samples on significantly more patients than in a previously comparable period in 2001. Facsimile cascade assists effective communication with primary-care physicians in an outbreak investigation.

Complement Fixation Tests↗

PubMed2000

Different diagnostic methods for detection of influenza epidemics.

Linking continuous community-based morbidity recording of influenza-like illness (ILI) with virological sampling has consistently proved its value as one of the earliest indicators of circulating influenza activity. The clinical morbidity recording in the Portuguese national surveillance network, during a 7-year period, and the contribution of different diagnostic techniques, including virus isolation, multiplex RT-PCR, immunocapture enzyme linked immunoassay (EIA) and complement fixation tests (CFTs) for the detection of influenza in such a community-based setting is described and evaluated in this study. There was good correlation between the increase of morbidity, total samples taken and the detection of influenza virus by all the methods although this was less evident for virus isolation and EIA than for RT-PCR or serology. From a total of 1685 throat swabs collected from cases of ILI, 43.6% were RT-PCR positive, 17.5% were positive by capture EIA and in 5% virus isolates were made. The detection of influenza by RT-PCR occurred earlier than by any other method and showed the best correlation with epidemic patterns of morbidity registration. We conclude that in surveillance systems where virus culture is sub-optimal, RT-PCR provides a rapid, sensitive, specific method for detecting influenza viruses from community-based sampling.

Complement Fixation Tests↗

PubMed1998

The detection by enzyme-linked immunosorbent assays of non-complement-fixing HLA antibodies in transfusion medicine.

BACKGROUND: Noncomplement-fixing white cell antibodies have been demonstrated by the use of immunofluorescence flow cytometry against intact lymphocytes. However, such antibodies may be either HLA-specific or directed against other white cell antigens. Commercial enzyme-linked immunosorbent assay (ELISA) kits, using solubilized HLA molecules as targets, enable such HLA-specific antibodies to be detected in patients who are refractory to platelet transfusion, patients experiencing febrile transfusion reactions, and patients whose sera give nonspecific hemagglutination in indirect antiglobulin tests. STUDY DESIGN AND METHODS: Sera from all three groups of patients, previously screened for cytotoxic antibodies by using complement-dependent lymphocytotoxicity, were re-investigated with commercial ELISA kits for HLA antibody screening and identification using the manufacturers' recommended test methods. RESULTS: Non-complement fixing HLA antibodies were detected by ELISA in many sera that were lymphocytotoxicity test-negative; that is, 14 (17.5%) of 80 from refractory patients, 8 (23.5%) of 34 from those with febrile reactions, and 11 (22.4%) of 49 from those with nonspecific hemagglutination in the direct antiglobulin test. However, not all cytotoxic white cell antibodies were detectable by ELISA: only 19 (82.6%) of 23, 19 (67.8%) of 28, and 11 (73.6%) of 49, respectively in the three groups. Similarly, only 143 (79.4%) of 181 cytotoxic sera with clear-cut HLA-A or -B locus specificities were detectable by ELISA. CONCLUSION: ELISAs detect some but not all clinically significant HLA antibodies, irrespective of their ability to fix complement in vitro.

Complement Fixation Tests↗